文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

从奥密克戎BA.4/5优势期汲取经验:未来疫苗接种准备策略

Learning from the omicron BA.4/5 dominance: Strategies for future vaccination preparedness.
PubMed 文献 · Vaccine · 2025-12-03

该研究基于香港1737475名成人的全港观察性研究,评估不同新冠加强策略对奥密克戎BA.4/5的保护效果及免疫史顺序影响。结果显示平台转换异源加强、二价疫苗及先接种后感染策略均提供更优保护,为未来大流行疫苗接种策略提供循证原则。

要点

  • 平台转换异源加强(灭活转mRNA)较同源策略降低感染风险9-21%。
  • 二价奥密克戎BA.4/5 BNT162b2疫苗较标准BNT162b2降低风险30-58%。
  • 先接种后感染策略始终优于先感染后接种,尤其对CoronaVac接种者。

核心结论

  • 平台转换异源加强(灭活疫苗转mRNA疫苗)为灭活疫苗受种者提供有意义的优势。
  • 二价疫苗提供实质性额外保护。
  • 先接种后感染策略始终优于先感染后接种场景。
  • 研究结果支持主动疫苗接种政策而非依赖感染获得性免疫。

研究设计与样本

  • 采用Andersen-Gill模型评估不同疫苗接种和感染史队列的感染风险,比较同源与异源加强、二价与标准疫苗、先接种与先感染策略。

主要发现

  • 平台转换异源加强(灭活转mRNA疫苗)较同源策略降低感染风险9-21%。
  • 二价奥密克戎BA.4/BA.5 BNT162b2疫苗较标准BNT162b2疫苗选项风险降低30-58%。
  • 先接种后感染场景较先感染场景持续提供更优保护,先感染CoronaVac受种者后续感染风险高97-141%。
  • 免疫暴露的时间顺序对最终保护效益至关重要。

临床怎么用

  • 对灭活疫苗受种者,可优先考虑平台转换异源加强(转mRNA疫苗)以提升保护。
  • 在可选情况下,优先使用二价奥密克戎BA.4/5 BNT162b2疫苗而非标准BNT162b2疫苗。
  • 推行主动疫苗接种策略,不应依赖感染获得性免疫。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the protective effectiveness of various COVID-19 booster strategies against the Omicron BA.4/5 variant and examine the impact of vaccination-infection sequence on subsequent immunity, focusing on individuals with waned immunity (>6 months since last vaccination/infection). METHODS: We conducted a territory-wide observational study of 1,737,475 adults in Hong Kong during the BA.4/5-dominant period (November 2022-January 2023). The Andersen-Gill model was employed to assess infection risks across different vaccination and infection history cohorts, comparing homologous versus heterologous boosting strategies, bivalent versus standard vaccines, and vaccination-first versus infection-first approaches. RESULTS: Platform-switching heterologous boosting (inactivated to mRNA vaccines) reduced infection risk by 9-21 % compared to homologous strategies. Bivalent Omicron BA.4/BA.5 BNT162b2 vaccines provided 30-58 % lower hazard versus standard BNT162b2 vaccine options. Vaccination before infection consistently yielded superior protection compared to infection-first scenarios, with infection-first CoronaVac recipients facing 97-141 % higher subsequent infection risk. The temporal sequence of immune exposures proved critical in determining ultimate protective benefits. CONCLUSIONS: This study provides evidence-based principles for future pandemic vaccination strategies. Platform-switching heterologous boosting (from inactivated vaccines to mRNA vaccines) offers meaningful advantages for inactivated vaccine recipients, bivalent vaccines provide substantial additional protection, and vaccination-first approaches consistently outperform infection-first scenarios. These findings support proactive vaccination policies over reliance on infection-acquired immunity and inform rapid response strategies for future pandemic threats.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Jiang J, Lam KF, Lau EHY, et al. Learning from the omicron BA.4/5 dominance: Strategies for future vaccination preparedness. Vaccine. 2025. PMID: 41343988. doi:10.1016/j.vaccine.2025.128058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。